Observing the Burden and Clinical Features of Atypical Hemolytic Uremic Syndrome in Egyptian Hospitals A Multicenter Retrospective Study

What this Trial Is About

Atypical hemolytic uremic syndrome aHUS is a rare and serious disease that can occur at any age, characterized by damage to small blood vessels and often impacting the kidneys. This condition is linked to problems with the complement system, sometimes caused by genetic mutations or antibodies. The disease has a high mortality rate and can lead to kidney failure requiring dialysis. Since specific treatments like complement inhibitors are not yet available in Egypt, this study focuses on understanding the impact of aHUS on patients in Egyptian hospitals, aiming to improve diagnosis and management. This research is an observational, retrospective cohort study conducted across multiple centers in Egypt. It aims to collect information from patient records dating from 2010 to 2023, including demographic and clinical data, disease progression, and treatment outcomes. The study will estimate how common aHUS is among patients with thrombotic microangiopathy TMA and examine real-world treatment patterns and results, as no prior data exists from the country. Participants medical records will be reviewed over a 10-year period to gather detailed information about their aHUS diagnosis, clinical characteristics, and long-term complications. The study will assess treatment outcomes and patterns during this time. Since this is an observational study, there are no interventions or treatments assigned by the study. The total duration for outcome measurement is 10 years, allowing for a comprehensive understanding of disease burden and management in Egypt.

The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt